Phathom announces first patient dosed in Phase 2 pHalcon-EoE-201 trial

Phathom Pharmaceuticals (PHAT) announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA tablets as an investigational treatment for eosinophilic esophagitis in adults. “The initiation of the pHalcon-EoE-201 study reflects Phathom’s commitment to advancing care for patients with gastrointestinal diseases and our development strategy to expand VOQUEZNA’s clinical potential,” said Steve Basta, President and Chief Executive Officer at Phathom. “This trial represents an important opportunity to address significant unmet needs in the treatment of EoE while potentially generating data to support discussions on a pediatric program that could ultimately extend VOQUEZNA’s regulatory exclusivity and strengthen our long-term growth strategy as leaders in GI.”